Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Cancer Res. 2011 Apr 21;71(13):4664–4674. doi: 10.1158/0008-5472.CAN-10-4447

Figure 4: A-Rafshort interacts with activated Ras inhibiting Ras-ERK signalling.

Figure 4: A-Rafshort interacts with activated Ras inhibiting Ras-ERK signalling

(A) Flag-tagged A-Rafshort or A-RafWT were transfected in HeLa cells. Cells were serum-starved for 16 hours (0.1% FCS) or serum-stimulated (10% FCS) for 5min after starvation as indicated. A-Raf isoforms were immunoprecipitated with flag-tag specific antibodies, and analysed by immunoblotting for the interaction with Ras. (B) Endogenous Ras was immunoprecipitated from lysates of HeLa cells, which had been serum starved (0.1% FCS, 16 hours) or treated with full medium (10% FCS) after serum-starvation using a specifc antibody for Ras, and analysed by immunoblotting (upper panel). As an isotype control, an antibody specific for GFP was used (middle panel, ‘Isotype’). Lysates were immunoblotted for expression of A-Rafshort, Ras, B-Raf, phosphorylated ERK1/2, and ERK1/2 as loading control (lower panel). LC - light chain immunoglobulin. Shown are the representative results from three independent experiments. (C) A-Rafshort binds better to Ras. Either fixed or increasing amounts of Flag-tagged A-Rafshort or A-RafWT togther with HA-tagged H-Ras-V12 were transfected in HeLa cells as indicated. Cells were serum-starved for 16 hours (0.1% FCS) and serum-stimulated (10% FCS) for 5min after starvation. Ras complexes were immunoprecipitated, and analysed by immunoblotting for the A-Raf isoform interaction. (D) A-Rafshort inhibits Ras-induced cellular tranformation. NIH3T3 fibroblasts were tranfected with hyperactive Ras constructs. Cells were co-tranfected with either A-RafWT or A-Rafshort as indicated (left panel). Numbers indicate average number of foci per microgram of DNA (Ras constructs) (right panel). Error bars represent standard deviation of at least three independent experiments.

HHS Vulnerability Disclosure